Oral Azacitidine Wins FDA Approval for AML

Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.